Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 1
1953 2
1955 2
1956 1
1957 1
1959 1
1961 7
1962 5
1963 6
1964 7
1965 9
1966 5
1967 15
1968 8
1969 7
1970 7
1971 4
1972 4
1973 8
1974 2
1975 3
1976 11
1977 6
1978 8
1979 17
1980 24
1981 8
1982 20
1983 24
1984 23
1985 33
1986 26
1987 27
1988 18
1989 34
1990 40
1991 21
1992 37
1993 34
1994 36
1995 54
1996 41
1997 42
1998 50
1999 54
2000 45
2001 47
2002 56
2003 67
2004 66
2005 59
2006 85
2007 95
2008 99
2009 118
2010 144
2011 145
2012 149
2013 145
2014 175
2015 175
2016 147
2017 136
2018 177
2019 179
2020 211
2021 180
2022 182
2023 147
2024 144
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,573 results

Results by year

Filters applied: . Clear all
Page 1
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Maemondo M, et al. Among authors: morita s. N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530. N Engl J Med. 2010. PMID: 20573926 Free article. Clinical Trial.
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Saji S, Morita S, Toi M, Ohno S. Yamamoto Y, et al. Among authors: morita s. Cancer Sci. 2022 Sep;113(9):3169-3179. doi: 10.1111/cas.15474. Epub 2022 Jul 23. Cancer Sci. 2022. PMID: 35754298 Free PMC article. Clinical Trial.
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Oncology Group. Mitsudomi T, et al. Among authors: morita s. Lancet Oncol. 2010 Feb;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X. Epub 2009 Dec 18. Lancet Oncol. 2010. PMID: 20022809 Clinical Trial.
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Saito H, et al. Among authors: morita s. Lancet Oncol. 2019 May;20(5):625-635. doi: 10.1016/S1470-2045(19)30035-X. Epub 2019 Apr 8. Lancet Oncol. 2019. PMID: 30975627 Clinical Trial.
Crucial role of iron in epigenetic rewriting during adipocyte differentiation mediated by JMJD1A and TET2 activity.
Suzuki T, Komatsu T, Shibata H, Tanioka A, Vargas D, Kawabata-Iwakawa R, Miura F, Masuda S, Hayashi M, Tanimura-Inagaki K, Morita S, Kohmaru J, Adachi K, Tobo M, Obinata H, Hirayama T, Kimura H, Sakai J, Nagasawa H, Itabashi H, Hatada I, Ito T, Inagaki T. Suzuki T, et al. Among authors: morita s. Nucleic Acids Res. 2023 Jul 7;51(12):6120-6142. doi: 10.1093/nar/gkad342. Nucleic Acids Res. 2023. PMID: 37158274 Free PMC article.
Total Talar Replacement: Surgical Technique.
Taniguchi A, Tanaka Y, Miyamoto T, Morita S, Kurokawa H, Takakura Y. Taniguchi A, et al. Among authors: morita s. JBJS Essent Surg Tech. 2023 Apr 26;13(2):e22.00030. doi: 10.2106/JBJS.ST.22.00030. eCollection 2023 Apr-Jun. JBJS Essent Surg Tech. 2023. PMID: 38274145 Free PMC article.
Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy triple negative breast cancer tumors.
Nishimura T, Velaga R, Masuda N, Kawaguchi K, Kawaguchi S, Takada M, Maeshima Y, Tanaka S, Kikawa Y, Kadoya T, Bando H, Nakamura R, Yamamoto Y, Ueno T, Yasojima H, Ishiguro H, Morita S, Ohno S, Haga H, Matsuda F, Ogawa S, Toi M. Nishimura T, et al. Among authors: morita s. Cancer Sci. 2024 Dec;115(12):3928-3942. doi: 10.1111/cas.16339. Epub 2024 Oct 7. Cancer Sci. 2024. PMID: 39375938 Free PMC article.
3,573 results